Skip to content

AFS Securities at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$630.67M-7.4%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$0
Nuvation Bio logo
Nuvation BioNUVB
$365.13M-21.8%
Royalty Pharma logo
Royalty PharmaRPRX
$406.8M+85.8%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX

Other financials

Income statement

See full
Revenue$6.2M-96.1%
Operating income-$53.4M-148%
Net income-$50.0M-144%
EPS (diluted)-$0.79-142%

Balance sheet

See full
Cash & equivalents$155.7M-43.4%
Total debt$3.4M-42.5%
Total equity$394.9M+12.8%
Total assets$443.3M+8.9%

Cash flow

See full
Operating cash flow-$60.6M-146%
CapEx$353.0K+132%
Free cash flow-$60.9M-146%

Valuation

See full
Market cap$1.94B+436%
Enterprise value$1.79B+1,855%
P/S60.4×+58.5×

Profitability

See full
Operating margin-577.5%-597pp
Net margin-529.2%-556pp
FCF margin36.2%+18.4pp

Returns & leverage

See full
Return on equity-45.6%-66.1pp
Debt / equity0.0×
Current ratio+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.

The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stoke Therapeutics, Inc.'s afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stoke Therapeutics, Inc.'s AFS securities?
Stoke Therapeutics, Inc. (STOK) reported AFS securities of $67.48M in Q1 2026.
How has Stoke Therapeutics, Inc.'s AFS securities changed year-over-year?
Stoke Therapeutics, Inc.'s AFS securities increased by 193.5% year-over-year, from $22.99M to $67.48M.
What does AFS securities mean?
Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.